ClinicalTrials.gg
RecruitingNCT06782139ENVYUpdated Sep 2, 2025

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

A Phase 4 interventional study of Enavogliflozin and Placebo in Obesity and Type 2 Diabetes, sponsored by Korea University Anam Hospital. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Korea University Anam Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 137 studies in Obesity with a site in Korea, Republic of — 35 open to participants now, 46 under way, 27 of them phase 3. Obesity · Korea, Republic of.

Planned enrollment
100th of 117
30 · median 120
Started
2025
with 10 others
Phase 4
7 of 137
1 open now
Primary completion
2025-12
later than 10 of 45 live
Registered
102nd of 137
by date
Lead sponsor
4 of 137
Korea University Anam Hospital

Among the 137 studies in Obesity with a site in Korea, Republic of, this one is the 100th largest by planned enrollment of the 117 interventional ones that give a count, is one of 11 that started in 2025, is one of 7 in phase 4, reaches primary completion later than 10 of the 45 other live ones, and was the 102nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

35 of the 137 studies in Obesity with a site in Korea, Republic of are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Obesity with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.

Read the detailed description

In recent years, the prevalence of obesity has increased, which acts as a significant risk factor for cardiovascular diseases. Obesity is closely related to reduced microvascular function, increased insulin resistance, and elevated blood pressure, and it is particularly known to be a major cause of heart failure with preserved ejection fraction (HFpEF) and diastolic dysfunction. Coronary microvascular dysfunction (CMD) leads to angina, myocardial infarction, and heart failure, which are associated with increased mortality. CMD has recently gained more importance as one of the key mechanisms of HFpEF. However, CMD often shows poor response to standard treatments, and when not recognized by healthcare providers, it can result in poor outcomes due to a lack of appropriate treatment.

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors are drugs that inhibit glucose reabsorption by blocking SGLT2 in the proximal tubules of the kidneys, thereby lowering blood sugar. Initially developed as oral hypoglycemic agents, previous randomized controlled studies have shown that they also have significant beneficial effects on heart failure and cardiovascular diseases not only in diabetic patients but also in non-diabetic patients. Recent studies have also demonstrated the effectiveness of SGLT2 inhibitors in patients with HFpEF. SGLT2 inhibitors reduce excessive sodium excretion through urine, which reduces fluid volume, lowers blood pressure, and decreases body weight, but the exact mechanism of their significant effects in cardiovascular diseases is still not fully understood. In particular, research on the effects of SGLT2 inhibitors on microvascular function is still limited. Recently, a randomized controlled study involving 16 diabetic patients reported an increase in myocardial flow reserve after 4 weeks of dapagliflozin administration, while another study involving 90 high-risk cardiovascular diabetic patients showed no significant change in myocardial flow reserve at 13 weeks with empagliflozin. Regarding enavogliflozin, a recent animal study in pigs suggested that it could improve vascular function by intervening in coronary endothelial cell function.

This study hypothesized that enavogliflozin would improve microvascular abnormalities and enhance heart function and cardiopulmonary exercise capacity in obesity-related cardiovascular diseases. Therefore, the objective of this study is to analyze the effects of enavogliflozin on heart function and microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.

03

Conditions studied

  • Obesity and Type 2 Diabetes

Keywords

  • Sodium-Glucose Cotransporter 2 inhibitors
  • Obesity
  • Diabetes
  • Coronary microvascular function
  • Epicardial adipose tissue
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: The following criteria must be met for inclusion in the study:

  1. Obesity or Abdominal Obesity:

    (BMI) ≥ 25 kg/m², or Waist circumference: Male ≥ 90 cm, Female ≥ 85 cm.

  2. Diabetes:

≥ 6.5%, or Fasting blood glucose ≥ 126 mg/dL after 8 hours of fasting, or Currently on antidiabetic medication. Blood test results must be within 3 months prior to enrollment.

Other inclusion criteria:

Age between 20 and 79 years. Patients who have undergone coronary flow velocity reserve testing. For baseline echocardiography, left ventricular diastolic dysfunction will be evaluated structurally (LV dimension, LV mass index, LA size) and hemodynamically (Doppler data, , strain data).

Exclusion Criteria:

  1. Left ventricular ejection fraction (LVEF) \< 50%
  2. History of coronary artery disease, or patients who have undergone coronary artery intervention or coronary artery bypass grafting.
  3. Patients with suspected obstructive coronary artery disease, including those with chest pain and positive stress test results (e.g., exercise treadmill test, dobutamine stress echocardiography, myocardial perfusion imaging).
  4. Second-degree or higher atrioventricular block, symptomatic bradycardia, sick sinus syndrome, or Wolff-Parkinson-White syndrome.
  5. Chronic kidney disease ( \< 30 mL/min/1.73 m²) or end-stage renal disease on hemodialysis or peritoneal dialysis.
  6. Asthma, , or primary pulmonary hypertension.
  7. Moderate or severe valvular heart disease or congenital heart disease, or patients with a history of open-heart surgery.
  8. Active cancer within the last 5 years, or patients currently receiving chemotherapy.
  9. Vasculitis associated with diseases, such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
  10. Patients who cannot undergo exercise testing, such as treadmill or bicycle ergometer testing.
  11. Use of any other SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) within the past 6 months, or a known allergy to these drugs.
  12. Pregnant or breastfeeding women.
  13. Women planning pregnancy during the study period (or within 24 weeks from the start of the study, including the 12-week observation period).
  14. Acute urinary tract infection at the time of enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Enavogliflozin

    The medication is a soft, orange, bi-convex, triangular film-coated tablet, and it is administered once daily at a dose of 0.3 mg, regardless of meals.

    Drug: Enavogliflozin

  • Placebo comparator
    Placebo

    The placebo is provided by the pharmaceutical company in the form of a tablet that is identical in size, shape, taste, and odor to the active intervention medication.

    Drug: Placebo

Interventions

  • Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.

  • DrugPlacebo

    Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.

06

What researchers measure

Primary outcomes

  1. Coronary microvascular function

    The changes in coronary flow velocity reserve at 12 weeks compared to baseline in the active drug/placebo groups

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Cardiopulmonary exercise capacity (VO2peak, mL/min/kg)

    The changes in cardiopulmonary exercise capacity ((VO2peak, mL/min/kg) at 12 weeks compared to baseline in the active drug/placebo groups

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Body weight (kg)

    Changes in body weight (kg) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Systolic and diastolic blood pressure (mmHg)

    Changes in Systolic and diastolic blood pressure (mmHg) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Waist circumference (cm)

    Changes in waist circumference (cm) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  5. Lipid profile

    Changes in total cholesterol (mg/dL), triglycerides (mg/dL), high-density lipoprotein cholesterol (mg/dL), and low-density lipoprotein cholesterol (mg/dL) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  6. Hemoglobin A1c (%)

    Changes in hemoglobin A1c (%) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  7. NT-proBNP (pg/mL)

    Changes in NT-proBNP (pg/mL) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  8. Self-assessment of sarcopenia (score)

    Changes in self-assessment of sarcopenia (score) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  9. 5-time chair rise test (sec)

    Changes in 5-time chair rise test (sec) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  10. Body composition analysis - skeletal muscle mass index

    Changes in skeletal muscle mass index (kg/m2) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  11. Body composition analysis - visceral fat area

    Changes in visceral fat area (cm2) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  12. Echocardiographic findings - chamber size (mm)

    Changes in chamber size (mm) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  13. Echocardiographic findings - ejection fraction (%)

    Changes in ejection fraction (%) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  14. Echocardiographic findings - E/e'

    Changes in E/e' at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  15. Echocardiographic findings - global longitudinal strain (%)

    Changes in global longitudinal strain (%) at 12 weeks compared to baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

  16. Epicardial Adipose tissue

    % change of EAT from baseline to 12weeks

    Time frame: % change of EAT from baseline to 12weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 11 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Jan 17, 2025
StartActual
Jan 20, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06782139
Responsible party
Seong-Mi Park, M.D. Ph.D. (Professor, Korea University Anam Hospital) — Principal investigator
First posted
Jan 17, 2025
Start date
Jan 20, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 2, 2025

Study contacts

So Ree Kim, MD, PhD
Contact
soree8826kim@gmail.com
82029205445
Seong-Mi Park, M.D., Ph.D.
Contact
smparkmd@korea.ac.kr
82029205445
Seong-Mi Park, M.D., Ph.D.
principal investigator · Korea University Anam Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion